2525 completed. 2525 Phase 3, 392 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2525 | Completed 2525 |
| Phase 2 | 392 | Completed 392 |
Follow Mental Disorders: new trials by email Literature Review of Mental Disorders trials Research Report on Mental Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intranasal Insulin to Prevent Intensive Care Unit Delirium Intranasal insulin-40U, Intranasal sodium chloride 0.9% - Delirium - Postoperative | Phase 2 / Phase 3 | Completed | Radboud University Medical Center | 30 | 2026-04-30 | 2026-08-03 |
| Comparing Haloperidol to Olanzapine in the Treatment of Suspected Cannabinoid Hyperemesis in the Emergency Department Olanzapine 10 milligram, Haloperidol - Cannabinoid Hyperemesis Syndrome | Phase 3 | Completed | Mercy Bon Secours Saint Vincent Medical Center | 31 | 2025-11-06 | 2026-10-14 |
| A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD LPCN 1154A, Placebo - Depression, Postpartum, Depression, Post-Partum | Phase 3 | Completed | Lipocine Inc. | 90 | 2025-06-16 | 2026-02-24 |
| P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety Centanafadine, Placebo - ADHD, Anxiety | Phase 3 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 315 | 2025-03-26 | 2026-05-06 |
| Safety and Efficacy Study of YZJ-1139 Tablets in Insomnia Disorder YZJ-1139, Zolpidem - Insomnia Disorder | Phase 3 | Completed | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | 61 | 2025-03-25 | 2026-06-29 |
| Efficacy of a Multidomain Intervention on Lifestyle Risk Factors for Dementia Prevention Luci Coach-Assisted Intervention - Risk Behavior, Cognitive Decline | Phase 3 | Completed | LuciLab | 368 | 2025-03-13 | 2026-11-02 |
| Dexmedetomidine in Reducing Postoperative Delirium in Cardiac Surgery Patients Dexmedetomidine nasal spray - Postoperative Delirium, Preoperative Sleep Disorder | Phase 3 | Completed | Xijing Hospital | 686 | 2025-03-03 | 2026-09-11 |
| Reducing Breathlessness With Dronabinol in COPD Patients Dronabinol 2.5mg Capsule, Placebo - COPD, Breathlessness | Phase 3 | Completed | Vejle Hospital | 30 | 2025-02-26 | 2026-10-05 |
| The Research of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression Ammoxetine, Placebo, Sertraline - Major Depressive Disorder (MDD) | Phase 3 | Completed | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 786 | 2025-02-21 | 2026-10-30 |
| Actual Use Trial of Tadalafil 5 mg Tadalafil 5 mg tablets with a digital tool. - Erectile Dysfunction | Phase 3 | Completed | Sanofi | 2212 | 2025-01-30 | 2026-07-13 |
| "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" CYB003, Psychological Support, Placebo - Major Depressive Disorder | Phase 3 | Completed | Cybin IRL Limited | 223 | 2024-12-17 | 2026-10-27 |
| Melatonin fOr CHronic bAck Pain (The MOCHA Trial) Melatonin 10 MG, Placebo - Back Pain Lower Back Chronic, Insomnia | Phase 3 | Completed | Odense University Hospital | 220 | 2024-12-11 | 2026-04-22 |
| A Study to Evaluate the Efficacy and Safety of Daridorexant in Participants With Insomnia Disorder Daridorexant, Placebo - Insomnia Disorder | Phase 3 | Completed | Nxera Pharma Korea Co., Ltd. | 164 | 2024-12-04 | 2026-01-21 |
| Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effect of KarXT in Participants With Schizophrenia KarXT - Schizophrenia | Phase 3 | Completed | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 173 | 2024-10-28 | 2026-06-22 |
| Efficacy and Safety Study of Levomilnacipran Hydrochloride Extended-Release Capsules in Major Depressive Disorder Levomilnacipran Hydrochloride Extended-Release Capsules, Duloxetine Hydrochloride Enteric Capsules - Major Depressive Disorder (MDD) | Phase 3 | Completed | Zhejiang Huahai Pharmaceutical Co., Ltd. | 392 | 2024-10-17 | 2025-11-28 |
| Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR) Injectable extended-release buprenorphine, Sublingual buprenorphine-naloxone - Opioid-Related Disorders, Substance-Related Disorders | Phase 3 | Completed | Yih-Ing Hser | 140 | 2024-10-14 | 2026-04-29 |
| Virtual Reality Treatment for Emerging Adults With ADHD Meta Quest 3 VR Headset with noise cancelling headphones - Attention Deficit Hyperactivity Disorder | Phase 3 | Completed | Rutgers, The State University of New Jersey | 60 | 2024-09-20 | 2026-01-02 |
| Efficacy of BNC210 in Acute, As-needed Treatment of Anxiety in Social Anxiety Disorder - 1 225 mg BNC210, Placebo - Social Anxiety Disorder | Phase 3 | Completed | Bionomics Limited | 370 | 2024-08-06 | 2026-05-19 |
| Safety and Efficacy of FT218 in Idiopathic Hypersomnia (REVITALYZ) FT218, Placebo - Idiopathic Hypersomnia | Phase 3 | Completed | Avadel | 157 | 2024-08-01 | 2026-05-11 |
| Study of Lumateperone in the Treatment of Patients With Bipolar Mania Lumateperone, Placebo - Bipolar Disorder, Manic | Phase 3 | Completed | Intra-Cellular Therapies, Inc. | 351 | 2024-07-17 | 2026-07-24 |
Showing 20 of 2525. Sign in to see all of them.
Schizophrenia (345) · Depressive Disorder, Major (322) · Depression (239) · Alzheimer Disease (193) · Attention Deficit Disorder with Hyperactivity (191) · Bipolar Disorder (177) · Anxiety Disorders (135) · Sleep Initiation and Maintenance Disorders (129) · Psychotic Disorders (106) · Alcoholism (87) · Opioid-Related Disorders (85) · Substance-Related Disorders (84) · Dementia (80) · Erectile Dysfunction (79)
Nervous System Diseases (665) · Mood Disorders (529) · Behavior (425) · Pathological Conditions, Signs and Symptoms (388) · Schizophrenia Spectrum and Other Psychotic Disorders (376) · Chemically-Induced Disorders (352) · Neurocognitive Disorders (344) · Signs and Symptoms (339) · Depressive Disorder (319) · Central Nervous System Diseases (300) · Neurodevelopmental Disorders (299) · Behavioral Symptoms (293) · Brain Diseases (284) · Substance-Related Disorders (269)
Risperidone (84) · Aripiprazole (79) · Quetiapine Fumarate (67) · Olanzapine (54) · Escitalopram (45) · Cognitive Behavioral Therapy (44) · Methylphenidate (43) · Paliperidone Palmitate (43) · Duloxetine Hydrochloride (38) · Sertraline (37) · Buprenorphine (35) · Vortioxetine (35) · Lurasidone Hydrochloride (31) · Therapeutics (31) · Naltrexone (30)
Eli Lilly and Company (88) · Otsuka Pharmaceutical Development & Commercialization, Inc. (83) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (74) · AstraZeneca (61) · H. Lundbeck A/S (48) · Sanofi (41) · Sumitomo Pharma America, Inc. (39) · GlaxoSmithKline (36) · Forest Laboratories (32) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (32) · Shire (32) · Yale University (32) · New York State Psychiatric Institute (31) · Takeda (29) · Organon and Co (27)
United States (1464) · Canada (293) · Germany (233) · France (221) · Spain (162) · Russia (159) · Poland (143) · United Kingdom (137) · Australia (117) · Bulgaria (114) · Italy (113) · South Korea (112) · Japan (111) · Ukraine (111) · Sweden (102)
PMID 37811711, PMID 40342086, PMID 25758058, PMID 39498781, PMID 24816198, PMID 25019647, PMID 26644956, PMID 37142273, PMID 26709542, PMID 29140227, PMID 34183490, PMID 24067192, PMID 24175720, PMID 26474010, PMID 37230961, PMID 21059176, PMID 24119319, PMID 24571916, PMID 27780334, PMID 31577867, PMID 31818787, PMID 34510411, PMID 34817851, PMID 36708956, PMID 39800465, PMID 20537128, PMID 20537130, PMID 21102344, PMID 22198451, PMID 23485955, PMID 23497790, PMID 24423017, PMID 26120369, PMID 26402769, PMID 26644957, PMID 27685842, PMID 28433500, PMID 30508090, PMID 32860422, PMID 33600233, PMID 33854317, PMID 33971070, PMID 34091867, PMID 34235612, PMID 34523063, PMID 34523118, PMID 34611902, PMID 36375174, PMID 36847750, PMID 37656180
2008 (21), 2016 (14), 2015 (13), 2009 (11), 2018 (10), 2004 (9), 2014 (9), 2017 (8), 2019 (8), 2005 (5), U01AG010483 (5), 2023 (4), U10DA013732 (4), P50DA009253 (3), R01DK049587 (3)